Long-term Efficacy of Interferon in Severe Uveitis Associated with Behçet Disease

Ocul Immunol Inflamm. 2017 Feb;25(1):76-84. doi: 10.1080/09273948.2016.1206204. Epub 2016 Aug 19.

Abstract

Purpose: To retrospectively assess the frequency of ocular relapse and the possibility of long-term remission in patients treated with interferon (IFN) for severe uveitis associated with Behçet disease.

Methods: All patients were treated with an initial dosage of 3 million IU IFN three times a week. The main outcome measure was the number of relapses per person per year before, during, and after IFN treatment.

Results: Of 36 patients (67 eyes), 31 (86.1%) responded to IFN. The mean follow-up was 8.19 years. Twenty-one out of 36 patients discontinued IFN and 76% of these have not relapsed within 5.05 years after discontinuation. The mean relapse per person per year decreased significantly from 1.39 to 0.0496 (p = 1.82×10-10) during the treatment period and remained at 0.057 relapses per person per year after IFN discontinuation.

Conclusion: IFN efficiently decreases the relapse rate and seems to permit long-term remission even after discontinuation.

Keywords: Behçet disease; interferon therapy; panuveitis.

MeSH terms

  • Adolescent
  • Adult
  • Behcet Syndrome / diagnosis
  • Behcet Syndrome / drug therapy*
  • Behcet Syndrome / physiopathology
  • Child
  • Female
  • Follow-Up Studies
  • Humans
  • Immunologic Factors / therapeutic use*
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Male
  • Middle Aged
  • Panuveitis / diagnosis
  • Panuveitis / drug therapy
  • Panuveitis / physiopathology
  • Recombinant Proteins / therapeutic use
  • Recurrence
  • Retrospective Studies
  • Treatment Outcome
  • Uveitis, Posterior / diagnosis
  • Uveitis, Posterior / drug therapy*
  • Uveitis, Posterior / physiopathology
  • Visual Acuity / physiology

Substances

  • Immunologic Factors
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins